HANGZHOU, China, SHANGHAI and BOSTON - October 27, 2026 - Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clinical trial evaluating zemprocitinib, an investigational, selective, second-generation oral Janus kinase 1 (JAK1) inhibitor, in adult patients with moderate-to-severe active rheumatoid arthritis (RA) who had experienced inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARDs).

The study met its primary endpoint of ACR20 response and key secondary endpoints at Week 24, demonstrating a statistically significant improvement with zemprocitinib versus placebo (p

The Week 52 and Week 76 results further demonstrate continued improvements in all disease activity measurements and physical function during long-term treatment by Week 52 and sustained clinical responses through Week 76.